JonesResearch analyst Soumit Roy downgraded Oncolytics (ONCY) to Hold from Buy without a price target The company is continuing to actively search for a Chief Executive Officer, as well as exploring potential business development opportunities, the analyst tells investors in a research note. The firm says it needs to get a better understanding on Oncolytics’ path forward “as there is an immediate need for capital.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech’s Strategic Advances in Oncology: Promising Developments in Breast and Pancreatic Cancer Research
- Oncolytics Biotech’s Earnings Call: Optimism Amid Challenges
- Oncolytics Biotech Reports Q1 Results and Clinical Progress
- Oncolytics Biotech Reports Q1 2025 Financial Results
- Oncolytics Biotech Reports Promising Q1 Results and Advances in Cancer Treatment
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue